Recessive mutation in tetraspanin CD151 causes Kindler syndrome-like epidermolysis bullosa with multi-systemic manifestations including nephropathy by Vahidnezhad, Hassan et al.
Article0022-2836/© 2017 ElseviRecessive mutation in tetraspanin
CD151 causes Kindler syndrome-like
epidermolysis bullosa with
multi-systemic manifestations
including nephropathyHassan Vahidnezhada, b, 1, Leila Youssefiana, c, 1, Amir Hossein Saeidiana,
Hamidreza Mahmoudid, Andrew Touati a, e, Maryam Abiri f,
Abdol-Mohammad Kajbafzadehg, Sophia Aristodemouh, Lu Liuh, John A. McGrath i,
Adam Ertel j, Eric Londin j, Ariana Kariminejadk, Sirous Zeinali b, Paolo Fortina j, l and
Jouni Uittoa,m
a - Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia,
PA, USA
b - Molecular Medicine Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
c - Department of Medical Genetics, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
d - Department of Dermatology, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran
e - Drexel University College of Medicine, Philadelphia, PA, USA
f - Department of Medical Genetics and Molecular Biology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
g - Pediatric Urology Research Center, Department of Urology, Children's Hospital Medical Center, Tehran University of Medical
Sciences, Tehran, Iran
h - Viapath, St Thomas' Hospital, London, UK
i - Department of Medical and Molecular Genetics, St. John's Institute of Dermatology, King's College London (Guy's Campus),
London, UK
j - Computational Medicine Center, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA
k - Kariminejad-Najmabadi Pathology & Genetics Center, Tehran, Iran
l - Department of Molecular Medicine, Sapienza University, Rome, Italy
m - Jefferson Institute of Molecular Medicine, Thomas Jefferson University, Philadelphia, PA, USA
Correspondence to Jouni Uitto: Department of Dermatology and Cutaneous Biology, Sidney Kimmel Medical College,
Thomas Jefferson University, 233 S. 10th Street, Suite 450 BLSB, Philadelphia, PA 19107, USA. Jouni.Uitto@Jefferson.edu
https://doi.org/10.1016/j.matbio.2017.11.003Abstract
Epidermolysis bullosa (EB) is caused by mutations in as many as 19 distinct genes. We have developed a
next-generation sequencing (NGS) panel targeting genes known to be mutated in skin fragility disorders,
including tetraspanin CD151 expressed in keratinocytes at the dermal-epidermal junction. The NGS panel
was applied to a cohort of 92 consanguineous families of unknown subtype of EB. In one family, a
homozygous donor splice site mutation in CD151 (NM_139029; c.351 + 2T N C) at the exon 5/intron 5 border
was identified, and RT-PCR and whole transcriptome analysis by RNA-seq confirmed deletion of the entire
exon 5 encoding 25 amino acids. Immunofluorescence of proband's skin and Western blot of skin proteins
with a monoclonal antibody revealed complete absence of CD151. Transmission electron microscopy showed
intracellular disruption and cell-cell dysadhesion of keratinocytes in the lower epidermis. Clinical examination
of the 33-year old proband, initially diagnosed as Kindler syndrome, revealed widespread blistering,
particularly on pretibial areas, poikiloderma, nail dystrophy, loss of teeth, early onset alopecia, and
esophageal webbing and strictures. The patient also had history of nephropathy with proteinuria. Collectively,
the results suggest that biallelic loss-of-function mutations in CD151 underlie an autosomal recessive
mechano-bullous disease with systemic features. Thus, CD151 should be considered as the 20th causative,
EB-associated gene.
© 2017 Elsevier B.V. All rights reserved.er B.V. All rights reserved. Matrix Biol. (2018) 66, 22–33
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Complexity of the basement membranes
Basement membranes comprise of complex net-
works of interacting matrix macromolecules separat-
ing epithelia from the underlying mesenchymal
tissues where they play physiologically important
roles [1]. In the skin, the dermal-epidermal basement
membrane is responsible for stable adhesion of
epidermis to the underlying dermis [2,3]. The pres-
ence of distinct basement membrane components,
their appropriate supramolecular assembly and their
macromolecular interactions are critical for the func-
tional integrity of these structures. While most
basement membranes universally consist of the
principal components, such as type IV collagen,
laminin-111 and heparin sulfate proteoglycans, cer-
tain basementmembranes have characteristic protein
components in a restricted tissue distribution critical
for their specialized tissue-specific function. For
example, in the skin, hemidesmosomes, critical
attachment complexes, consist of type XVII collagen,
α6β4 integrin and tetraspanin CD151 [4,5]. The
hemidesmosomes connect the intermediate filament
network, consisting of keratins 5 and 14 in the
intracellularmilieu of basal keratinocytes, to anchoring
filaments, extracellular filamentous structures which
traverse lamina lucida and consist primarily of
laminin-332. On the dermal side of the cutaneous
basement membrane zone, anchoring fibrils, com-
prised of type VII collagen, stabilize the association of
lamina densa to the underlying dermis [6]. The
contiguous network of hemidesmosomes, anchoring
filaments and anchoring fibrils is required for stable
association of the epidermis to the underlying dermis.
Phenotypic and genotypic heterogeneity of
epidermolysis bullosa
Mutations in the cutaneous basement membrane
zonegenes can result in fragility of the skin,which as a
result ofminor trauma leads to blistering and erosions.
The prototype of such heritable skin fragility disorders
is epidermolysis bullosa (EB), currently known to be
associated with mutations in as many as 19 distinct
genes [7–10]. The topographic level of expression of
these EB-associated genes within the basement
membrane zone, the types and combinations of
mutations and their consequences at the mRNA and
protein levels, when juxtaposed to environmental
factors, primarily external trauma, result in consider-
able phenotypic heterogeneity noted in this group of
disorders. In addition to cutaneous findings, some
forms of EB are associated with extracutaneous
manifestations in the ocular, gastrointestinal, pulmo-
nary, and vesico-urinary systems [11]. Combinations
of skin fragility and extracutaneous manifestationscan lead to considerable morbidity and in some cases
early mortality.
The tetraspanin family of proteins
Tetraspanins consist of a superfamily of transmem-
brane proteins widely distributed on a variety of cell
types, and they have been implicated in a broad
spectrum of cellular processes under physiological
conditions [12]. Specifically, tetraspanins form spe-
cialized membrane microdomains on the cell surface
controlling cell proliferation and migration, angiogen-
esis and adhesion. The expression of various tetra-
spanins has also been shown to be associated with a
number of different human malignancies with patho-
mechanistic roles as well as serving as prognostic
markers [13,14]. Tetraspanin CD151 is widely distrib-
uted in different tissues, including epithelium, endo-
thelium, muscle, renal glomeruli and proximal and
distal tubules [15]. This protein is also expressed in the
epidermis and has been shown to be a component of
the hemidesmosomes [4,5]. Tetraspanin CD151 is an
endogenous component of basement membranes in
the skin, in hemidesmosomes and focal adhesions,
where it forms stable laminin-binding complexes with
α3β1 and α6β4 integrins, as well as in the kidneys
where it interacts with α3β1 and α6β1 integrins [16].
CD151 is a 253-amino acid protein with a single
N-glycosylation site, and immunoblotting reveals
bands of apparent molecular weights of 28 and
32 kDa representing unglycosylated and glycosylated
forms, respectively [17].
We have developed a next generation sequencing
(NGS) panel covering 21 skin fragility-associated
genes, including CD151, which was used to screen
for pathogenic sequence variants in EB. In this
study, we report a patient with a homozygous splice
site mutation in CD151 resulting in deletion of exon 5
corresponding to a transmembrane domain, associ-
ated with multi-system involvement, including skin
fragility with a Kindler syndrome-like phenotype
(Fig. 1).Results
Next generation sequencing identifies a
homozygous donor splice site mutation in CD151
We have developed a targeted NGS array covering
21 genes associated with skin fragility disorders,
specifically consisting of 18 genes previously shown
to harbor mutations in different forms of EB [7]. Three
additional genes that are not in the current classifica-
tion of EB but which are associated with inherited skin
fragility and therefore in the differential diagnosis ofEB
were included: CDSN and CHST8, associated with
peeling skin syndromes, as well as CD151 which has
Fig. 1. Clinical features of the proband with Kindler syndrome-like phenotype. Note facial freckling, loss of teeth,
pretibial blistering, nail dystrophy, and atrophy of the back of the hands. The patient also had esophagus webbing and
strictures. The patient is the only affected individual in the consanguineous family with first cousin parents.
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complex nephropathy and blistering phenotype (for
the list of all genes in the panel, see Materials and
Methods). The sequencing panel was applied to DNA
from 92 probands, each representing a distinct family,
with the clinical diagnosis of EB, based on history of
neonatal blistering and erosions of the skin. NGS,
followed by extensive bioinformatics analysis, identi-
fied in one proband a homozygous mutation,
NM_139029:c.351 + 2TNC, in CD151 affecting the
canonical donor splice site junction sequence, AG/gt
at the exon 5/intron 5 border (Fig. 2a). This mutation
was predicted to result in aberrant splicing affecting
exon 5. The presence of this mutation at the genomic
level was confirmed by PCR, followed by bi-directional
Sanger sequencing (Fig. 2c), and the patient's parents
were shown to be heterozygous carriers of this
mutation. Homozygosity mapping showed an ~10 Mb
run of homozygosity (ROH) harboring CD151 on
chromosome 11 (p.15.5-p.15.4).
Consequences of the CD151 mutation at
transcriptome level
To examine the consequences of the mutation
at transcriptional level and also to exclude other
possible mutations throughout the exome, RT-PCRand independently whole transcriptome sequencing
(RNA sequencing, RNA-seq) of mRNA isolated
from a skin biopsy were performed. Sanger
sequencing of RT-PCR product spanning exons 4–6
revealed the deletion of a segment of sequences
corresponding to exon 5 and consisting of 75
nucleotides, indicating that the deletion was in-frame
(Fig. 2c).
Recently, the potential utility of whole tran-
scriptome sequencing for clinical genetic evalua-
tion of Mendelian disorders was demonstrated
in COL6A1 muscular dystrophy and TIMMDC1
mitochondrial complex I deficiency cohorts [18,19].
We performed RNA-seq scanning of whole tran-
scriptome of our case, and the results confirmed
skipping of exon 5 of CD151. A Sashimi plot
was generated to visualize and quantify the
consequences of this splicing abnormality, which
identified a splicing event utilizing the donor
splicing site of exon 4 and the acceptor splicing
site of exon 6 in 91 out of 92 transcriptional
reads (Fig. 2b). The deleted sequence of the
mRNA encodes a segment of 25 amino acids in
positions 93–117 of the CD151, which by modeling
was shown to include the third transmembrane
segment within the EC2 domain of the protein
(Fig. 3a).
Fig. 2. Next generation sequencing reveals a homozygous splice-site mutation in the CD151 gene. (a) Screen shot of
the genomic sequence visualized by the Integrative Genomics Viewer demonstrating homozygous T-to-C transition
mutation which resides inCD151within the canonical splice-site sequence AG/gt at the exon 5/intron 5 border. (b) Sashimi
plot of RNA-seq reveals that the CD151 mutation results in skipping of the entire exon 5 consisting of 75 bp (lower panel,
red), as compared to splicing in control RNA (upper panel, blue). (c) The mutation was confirmed at the genomic level by
Sanger sequencing (upper panel), as well as at the cDNA level by RT-PCR using mRNA isolated from the patient's skin
sample as template (lower panel).
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ultrastructural levels
To examine the consequences of the mutation at
protein level, immunofluorescence of the patient's skin
was performed with a monoclonal anti-CD151 anti-
body. The specificity of this antibodywas confirmedby
Western analysis which identified a band of ~28 kDa
with protein isolated from control skin samples
(Fig. 3d). Parallel staining of control skin from an
unaffected, unrelated individual revealed strong linear
staining at the dermal-epidermal junction with some of
the staining extending to the lateral surfaces of the
basal keratinocytes (Fig. 3b). In contrast, immuno-
staining with the same antibody was completelynegative in the patient's skin, indicating the absence
of the epitope recognized by this antibody (Fig. 3c).
Western blot of protein isolated from a biopsy from the
patient's skin showed absence of CD151 (Fig. 3d).
Transmission electron microscopy of the patient's
skin showed both intracellular and intercellular
disruption and dysadhesion (Fig. 3e). Some cells
showed keratin filament aggregation and cytolysis,
and there was widening of spaces between some
cells with poor desmosomal connections. There was
an apparent increase in intercellular accumulation of
electron dense material and cellular debris. Hemi-
desmosomes appeared somewhat small with im-
paired keratin filament association. In contrast,
anchoring fibrils below the lamina densa were
Fig. 3. Consequences of mutation at protein and ultrastructural level. (a) The 253-amino acid tetraspanin CD151 protein
consists of four transmembrane domains and two extracellular loops (EC1, EC2). The EC2 contains specific regions
involved in homodimerization (A, B and E) and in interactions with other proteins, such as integrins (C and D). The deleted
25-amino acid peptide segment of CD151 (yellow amino acids) includes the third transmembrane spanning domain. The
amino acids included in the immunogen used for development of the monoclonal antibody used in this study are
designated by a blue rim. (b) Immunostaining of control skin with an anti-CD151 monoclonal antibody reveals linear
staining of the dermal-epidermal junction which extends to the lateral sides of basal keratinocytes. (c) Staining of the
patient's skin with the same antibody was entirely negative. The dashed line indicates the position of the basement
membrane zone. The sections were counterstained with DAPI (blue). (d) Western blot analysis of protein isolated from skin
biopsies from four age-matched controls (Ctrl 1–4) with a monoclonal antibody to CD151 reveals a band of 28 kDa, while
the patient's skin biopsy is devoid of CD151 protein (upper panel). Reprobing of the filter, after stripping, with an antibody to
β-actin reveals an abundance of protein as represented by the 42 kDa band (lower panel). (e) Transmission electron
microscopy of the patient's skin demonstrates intracellular and intercellular disruption and dysadhesion of basal
keratinocytes. There is widening of spaces between some cells with poor desmosomal connections. (f) Higher
magnification reveals accumulation of electron dense material and cellular debris. Hemidesmosomes appear somewhat
small with impaired keratin filament association, but anchoring fibrils are numerous and display normal ultrastructural
features.
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27CD151 as a cause of epidermolysis bullosanumerous and displayed normal ultrastructural
features (Fig. 3f).
Clinical features of the proband
The 33-year old proband with a homozygous
CD151 mutation was referred to this study with a
clinical diagnosis of Kindler syndrome (KS). He was
the only affected individual in the family with
evidence of consanguinity in a first-cousin marriage
(Fig. 1). Clinical examination of the proband revealed
features of KS with phenotypic overlap with some
forms of junctional EB, generalized intermediate,
including facial freckling, poikiloderma and atrophy
of the skin and acrogeria of the backs of the hands
on the sun-exposed areas. He had widespread
blistering and erosions primarily in the pretibial area
but also scattered on other parts of the body,
particularly those exposed to trauma. He also had
erosions in the oral mucous membranes. He was
completely edentulous and had anamnestically lost
all teeth by around 16 years of age (Fig. 1). The
patient had dystrophic nails in all fingers and toes,
and had early-onset alopecia. He had corneal
vascularization and symptomatic nasolacrimal duct
stenosis. He also had a history of difficulty with
swallowing, and barium radiography revealed
esophageal webbing and strictures (Fig. 1). The
patient had history of nephropathy manifesting with
proteinuria (for detailed clinical description, see
Case Report in Supplementary Material).Discussion
Epidermolysis bullosa is a phenotypically heteroge-
neous condition with highly variable severity. EB was
initially divided into three broad categories, viz.,
simplex, junctional and dystrophic subtypes, based
on the topographic level of tissue separationwithin the
cutaneous basement membrane zone [7]. More
recently, Kindler syndrome with neonatal blistering
has beenadded as the fourthmajor type of EB [20,21].
The phenotypic variability in EB reflects, to a large
part, genetic heterogeneity, and as many as 19
distinct genes expressed at the dermal-epidermal
basement membrane zone have been shown to
harbor mutations in different variants of EB [8,10].
The demonstration of mutations in the CD151 gene
brings this number to 20. Themutation reported in this
study leads to aberrant splicing of exon 5 and deletion
of 25 amino acids from the CD151 protein, with
profound consequences to the ultrastructure of basal
keratinocytes, including disintegration and dysadhe-
sion. Since no blisteringwas noted in the skin samples
used for immunofluorescence, it was not possible to
determine what distinct major category of EB the
CD151 deficiency belongs to. However, considering
the facts that the ultrastructural changes in this patientwere somewhat similar to those noted in patients with
mutations in the EXPH5 gene, a form of EB simplex
[22], and that CD151 is expressed in the basal
keratinocytes [23], one could classify inherited
CD151 pathology as an EB simplex variant. Immuno-
fluorescence and Western blot analysis of the
patient's skin showed complete absence of immuno-
staining. The precise epitope of the monoclonal
antibody, which was commercially available, is
unknown, but the immunogenic peptide used for
development of this antibody (Leu118-Phe215) re-
sides just outside of the deleted region in CD151 (see
Fig. 3a), and it is therefore likely that the absent
immunofluorescence staining in the patient's skin
reflects the absence of the protein which may have
become unstable as a result of the mutation.
The patient was referred to our laboratory for
genetic testing with the diagnosis of KS. His clinical
features were consistent with this diagnosis included
poikiloderma, facial freckling and acrogeria, as well as
skin blistering which was more severe during child-
hood and became more moderate in the adulthood.
Considering the diagnosis of KS, the FERMT1 gene
was first sequenced by Sanger technique but no
pathogenic sequence variants were found. A charac-
teristic ultrastructural feature of KS is blistering within
multiple levels of the dermal-epidermal adhesion zone
which results in reduplication of the cutaneous
basement membrane. The latter feature was not
evident in ultrastructural examination by transmission
electron microscopy, further suggesting subclassifi-
cation of this case as a formof EB simplexwith KS-like
clinical features. It should also be noted that the
proband had esophageal webbing and strictures,
features consistently associated with the recessive
dystrophic subtype of EB, but also reported in KS [24].
Moreover, the clinical features also showed some
overlap with generalized intermediate junctional EB
[7]. Thus, the proband has some KS-like features but
the overall clinical findings indicate a distinct clinico-
pathologic entity.
Our patient has clinical similarities to three MER2-
negative patients in two families of Indian Jewish
origin with end-stage renal disease (ESRD) with a
homozygous indel mutation c.383insG in CD151
causing a frame-shift and premature stop codon
(See Table 1) [25]. In addition to hereditary nephritis,
two of these patients had sensorineural deafness,
nasolacrimal duct stenosis and β-thalassemia minor,
as well as pretibial EB. The authors concluded that
CD151 is essential for the proper assembly of the
glomerular and tubular basement membrane in
kidney, has functional significance in the skin, is
probably a component of the inner ear, and could play
a role in erythropoiesis [25]. In our patient, there was
no evidence of sensorineural deafness, and analysis
of hemoglobin showed no evidence of β-thalassemia.
The fragility of skin in our patient wasmore severe and
extended from pretibial area to other parts of the body
Table 1. Comparison of pertinent phenotypic characteristics of the index patient in this report with those of the patients in a
previous report of CD151-associated disease. The findings present in these patients are also compared to those findings
generally associated with different types of epidermolysis bullosaa.
Clinical manifestations Present report Previous reportb Categories of EB typically associated with finding
Cutaneous
Blistering over bony prominences + (Extensive) + (Pretibial) DDEB-pt., RDEB-pt. [7]
Poikiloderma + N/A KS [21]
Nail dystrophy + + EBS, JEB, DEB, KS [7]
Alopecia + N/A JEB, RDEB [7]
Ocular
Ectropion + N/A JEB-gs, RDEB-gs, KS [38]
Nasolacrimal duct stenosis + + JEB, RDEB [39]
Oral
Oral mucosal involvement + N/A EBS-gs, JEB, DEB, KS [7]
Microstomia + N/A JEB-gs, RDEB, KS [40]
Dystrophic teeth + (Edentulous) + JEB, RDEB [11]; KS [21]
Gastrointestinal
Esophageal involvement + (Webbing and strictures) N/A JEB-gs [21], DEB [41], KS [21]
Gastroesophageal reflux + N/A EBS-gs, JEB, RDEB [41]
Malnutrition + N/A JEB, RDEB [7], KS [21]
Constipation + N/A DEB [42], KS [20]
Renal
Protein-wasting nephropathy + + (ESRD) JEB-rri [29], JEB-PA [43], RDEB [44]
Genitourinary
Distal vaginal agenesis N/A + Not reported
Urinary incontinence + N/A JEB, RDEB [41]; KS [21]
Other
Anemia – + (BT minor) JEB-gs [7], RDEB [7], KS [7]
Sensorineural hearing loss − (4 kHz notch) + RDEB [41]
a Abbreviations: N/A = information not available or not applicable; ESRD = End-stage renal disease; BT minor = Beta thalassemia
minor; EBS = Epidermolysis bullosa simplex; JEB = Junctional epidermolysis bullosa; DEB = Dystrophic epidermolysis bullosa; KS =
Kindler syndrome; DDEB-pt. = Dominant DEB pretibial; RDEB-pt. = Recessive DEB, pretibial; EBS-gs = EBS, generalized severe;
JEB-gs = JEB, generalized severe; RDEB-gs = RDEB, generalized severe; JEB-rri = JEB with respiratory and renal involvement;
JEB-pa = JEB with pyloric atresia.
b Karamatic Crew et al., 2004.
28 CD151 as a cause of epidermolysis bullosasubject to trauma (seeCaseReport in Supplementary
Material). Our patient had, however, renal disease
which was less severe than that in previously reported
MER2-negative cases which developed ESRD.
These phenotypic differences might reflect differ-
ences in the mutations and their consequences or
may result from genetic and environmental modifying
factors. Thus, the combination of overlapping findings
with inter-patient variability calls for identification of
additional patients with CD151 deficiency to further
elucidate genotype-phenotype correlations towards
understanding of theCD151associated disease in the
EB spectrum (Table 1).
The pathomechanistic details by which the exon-
skipping mutation in CD151, delineated in our study,
are likely to involve interactions with laminin-binding
integrins expressed within the basement membrane
zones. Specifically, CD151 has been demonstrated to
associatewith integrins α3β1, α6β1,α6β4 andα7β1 in
cells in culture and in vivo [16]. Severalmodel systems
have revealed that binding of CD151 with these
receptors, particularly with α3β1, strengthens their
association with laminins. The association of CD151
with α3β1 integrin has been shown to be regulated by
glycosylation of this laminin receptor, with consequent
changes in cell spreading, motility, degradation andintegrity of basement membranes [26]. The protein
sequencesmediating association of CD151withα3β1
integrin map within the large extracellular loop EC2
which spans the amino acid residues Tyr112-Leu220,
a region mostly outside of the deleted segment in the
mutant CD151 in our patient. However, various
deletions within the protein, particularly involving the
small extracellular loop and transmembrane domains,
including the third transmembrane domain deleted in
the mutant protein in our patient, prevent surface
expression of CD151mutants, and the mutant protein
accumulates in the rough endoplasmic reticulum and
is then redirected to the lysosomes [27]. Thus, the
absence of immunofluorescence staining with the
CD151 antibody used in our study may reflect
degradation of the mutant protein. CD151 associates
with α3β1 as well as by α6β4 integrin in the formation
of mature hemidesmosomes of the cutaneous base-
ment membrane, where this tetraspanin likely plays a
role in hemidesmosomal stability [28]. As a conse-
quence of a loss of functional CD151, compromised
interactions between laminin-332 and both α3β1 and
α6β4 integrin would result in perturbations in base-
ment membrane stability and a reduced functional
capacity as a layer stabilizing the association of the
epidermis to the underlying dermis. This basement
29CD151 as a cause of epidermolysis bullosamembrane pathology then results in a form of EB,
manifesting with blistering and erosions as a result of
trauma, as is evident in our proband. In support of this
notion are demonstrations that patients with homozy-
gous mutations in the ITGA3 gene encoding the
integrin α3 subunit result in disrupted basement
membrane structures and compromised barrier func-
tions in kidney, lung and skin, leading to multi-organ
disorder that includes congenital nephrotic syndrome,
interstitial lung disease, and EB [29]. In these patients
the renal and respiratory features predominate, and
the lung involvement accounts for the lethal course of
the disease at the early age.
The mechanisms by which CD151 deficiency
results in kidney failure have been examined in
Cd151-null mice that recapitulate the renal pathology
noted in human patients [30,31]. These mice devel-
oped proteinuria caused by focal glomerular sclerosis,
disorganization of the glomerular basement mem-
branes, and tubular cystic dilatation. Furthermore,
generation of podocyte-specific conditional knockout
mice for the integrin α3 subunit showed renal defects
similar to those in Cd151 knockout mice. These
observations support the overall conclusions that
CD151 plays a key role in strengthening adhesion of
keratinocytes mediated laminin-α3β1 integrin com-
plex in the epidermis and podocytes in the renal
tissue, resulting in a distinct phenotype of EB with
multi-system involvement, as observed in our patient.
The classification of EB continues to be evaluated,
refined and expanded with status updates published
in a series of international consensus reports
[7,32,33]. Over time, several new clinicopathologic
entities have been incorporated to the formal
classification of EB, notably with several new
subtypes of EB simplex being added in recent
years. Although the most recent classification from
2014 lists 18 candidate genes [7], a 19th gene,
KLHL24, has been widely accepted for inclusion
following a series of cases reported in 2016 and
2017 [9,10,34,35]. However, a number of other
genes/skin fragility disorders reside on the fringes
of the classification, not yet absorbed into the
mainstream listing. Our data here provide strong
justification for inclusion of CD151 officially as the
20th gene in the classification of EB.Materials and methods
Targeted next generation sequencing
DNA from 92 probands of families with unspecified
forms of EB was extracted from peripheral blood
samples taken from patients, their parents and other
clinically affected and unaffected family members
using a QIAamp DNA Blood Mini Kit (Qiagen,
Valencia, CA). This study was approved by theInstitutional Review Board of the Pasteur Institute of
Iran, and all subjects as well as parents of underage
patients gavewritten informed consent to participate in
research and gave their permission to publish their
images. DNA was examined with a Qubit 2.0
fluorometer (Life Technologies, Carlsbad, CA) for
concentration and quality. Target enrichment was
performed using TruSeq Custom Amplicon Kit
(Illumina Inc., San Diego, CA). The sequencing library
was designed by DesignStudio (Illumina Inc.), and
contained 21 genes (CD151, CDSN, CHST8,
COL17A1, COL7A1, DSP, DST, EXPH5, FERMT1,
ITGA3, ITGA6, ITGB4, JUP, KRT5, KRT14, LAMA3,
LAMB3, LAMC2, PKP1, PLEC1, and TGM5) divided
into 421 targets covered by 968 amplicons. This array
covered all coding exons, at least 20 bp of the flanking
intronic sequences at the intron-exon borders, and up
to 50 bp of 5'- and 3′-untranslated regions of these
genes. The amplicon panel was designed to cover
99% of the targeted bases, and a total of 36,724,892
reads were aligned to the human genome. The mean
coverage of the target region was 424×. DNA from the
probands, together with an Illumina control, were
multiplexed using dual indexing with 12 primary
indexes and 8 secondary indexes. Dual indexed
samples were normalized to be equimolar and pooled
together following manufacturer's recommendations.
The pool of 96 samples was sequenced on a single
MiSeq flow-cell (Illumina Inc.). DNA fragments were
sequenced using paired-end 225-nt reads using dual
indexes, which generated 8.94 Gbp. The reads were
aligned to theHumanGenome versionGRCh38 using
the Burrows-Wheeler Alignment (BWA) Tool
BWA-MEM algorithm. Prior to variant calling, GATK
tools RealignerTargetCreator, IndelRealigner, Base-
Recalibrator, andPrintReadswereused to preprocess
the aligned reads with local realignments and base
quality score recalibration for optimized accuracy.
Single nucleotide variants and insertions/deletions
were called using the Bayesian genetic variant
analysis tool FreeBayes [https://arxiv.org/abs/1207.
3907].
Single nucleotide variants and insertion/deletions
were annotated using ANNOVAR software, which
includes data from the 1000 genomes project, ClinVar,
dbSNP, and dbNSFP, a database of human non-
synonymous SNPs and their functional predictions
based on combined SIFT, Polyphen2, LRT, and
MutationTaster scores. Variants were initially filtered
to exclude loci with fewer than 5 supporting reads or
alternate allele fraction b0.25. Homozygous variants
were then prioritized for pathogenicity starting with
nonsense mutations followed by large deletions,
frameshift insertions/deletions, canonical splice sites,
and finally nonsynonymous point mutations with
deleterious effects as documented in ClinVar or
predicted by dbNSFP. In those samples without
homozygous deleterious mutation candidates, genes
were further analyzed for compound heterozygous
30 CD151 as a cause of epidermolysis bullosamutations comprising combinations of two or more
events including nonsense mutations, frameshift
insertions/deletions, canonical splice sites, and non-
synonymous point mutations.
Pathogenicity of identified variants was designat-
ed according to the American College of Medical
Genetics Standards, and sequence variants were
classified either as pathogenic, likely pathogenic, or of
unknown significance [36]. Population allele frequen-
cies were determined using the Exome Aggregation
Consortium (Exac.broadinsitute.org), the 1000 Ge-
nomes database (1000genomes.org), and GnomAD
(Gnomad.broadinsitute.org). The pathogenic/likely
pathogenic variants were confirmed by sequencing
of both alleles by Sanger sequencing. PCR was
performed using Taq polymerase (Qiagen), and the
products were bi-directionally sequenced using an
automated sequencer (AB3730; Applied Biosystems,
Foster City, CA, USA).
RNA extraction, cDNA synthesis, RT-PCR, PCR
and Sanger sequencing
Biopsied skin samples from the patient were
immediately placed in Invitrogen™ RNAlater™
Stabilization Solution and transferred to the laboratory
for extraction ofRNAusingTRIzol®Reagent (Ambion,
Life Technologies). Oneμg of DNase-treated total
RNA was reverse transcribed (SuperScript III First
Strand Synthesis System, Invitrogen # 18080–051)
using gene-specific and universal primers followed by
RNase H treatment to degrade the RNA. 2 μl of the
reverse transcription reaction mixture was used for
PCR reaction using a CD151 specific primer encom-
passing the exons 4–6. Polymerase Chain Reaction
(PCR)was performed using Taq polymerase (Qiagen)
according to the manufacturer's instructions. The
RT-PCR products were bi-directionally sequenced
using an automated sequencer (AB3730; Applied
Biosystems). In addition, exonic regions and their
flanking intronic sequences harboring pathogenic
variants which were captured by NGS panel of EB
associated genes were amplified and sequenced
using newly designed primers (sequences available
upon request), spanning all exons and ~50 bp of the
flanking intronic sequences.
RNAseq
Total RNA was extracted from a skin biopsy
obtained from the proband using TRIzol® Reagent
and quantified on a Nanodrop ND-100 spectropho-
tometer (Thermo Fisher Scientific, Wilmington, DE),
followed by RNA quality assessment on an Agilent
2200 TapeStation (Agilent Technologies, Palo Alto,
CA). Multiplexed library construction, workflow anal-
ysis and sequencing runs were performed following
standard Illumina protocols (Illumina, Inc., San
Diego, CA) using the TruSeq Stranded Total RNAkit with indexes from Set A (Cat #: RS-122-2301).
Paired-end (2 × 75) sequencing reads were gener-
ated on the Illumina NextSeq 500 platform and
stored in FASTQ format. TruSeq RNA adapter
sequences were trimmed from the reads prior to
alignment. Reads were aligned using STAR 2-Pass
version 2.5.2b [37] with the human genome version
hg38 as the reference genome and GENCODE V24
annotations. Only reads mapping uniquely to the
genome were maintained. During the mapping, a
first-pass alignment was performed to identify the
discovery of unannotated junctions. These junctions
were then used to create a new annotation file for the
second-pass alignment as recommended by the
STARmanual to enable sensitive junction discovery.
Immunofluorescence staining and
Western analysis
For immunofluorescence, skin sections (5 μm)
were air-dried and initially blocked with diluted normal
goat serum (Sigma-Aldrich, Dorset, UK), and then
incubated with anti-CD151 (clone ab33315, 11G5a,
Abcam, Cambridge, UK) diluted 1:10 in phosphate-
buffered saline with 30% w/v bovine serum albumin
(Sigma-Aldrich). After washing in phosphate-buffered
saline, slides were labeled with fluorescein isothiocy-
anate secondary antibodies (Invitrogen, Paisley, UK).
Negative controls omitting the primary antibody were
also performed. All sectionswere photographed using
the same camera and identical exposure times (3 s).
ForWestern analysis, skin biopsy samples from the
patient and normal healthy individuals were collected
and homogenized by sonication in lysis buffer. The
protein concentrations were determined using the
Qubit Protein assay kit (ThermoFisher, Waltham,
Massachusetts, USA). Equal amounts of total protein
(80 μg) were loaded onto 4–20% gradient gels for
electrophoresis, followed by transfer to polyvinylidene
difluoride membranes. Membranes were blocked in
5% milk followed by incubation with the primary
polyclonal rabbit ant i-human antibody for
HPA011906 CD151 at 1:1000 (Sigma Aldrich, MO,
USA) with a secondary goat anti-rabbit antibody
925-32211 (LI-COR, Lincoln, Nebraska USA) at
1:15,000. The housekeeping protein beta-actin was
analyzed using the primary monoclonal mouse
anti-human antibody ab8224 at 1:20,000 (Abcam,
Cambridge, MA, USA) with a secondary goat
anti-mouse 926-32210 at 1:20,000 (LI-COR). Mem-
branes were visualized using the Odyssey CLx
near-infrared fluorescence imaging system (LI-COR).
Transmission electron microscopy
Skin biopsy specimens were cut into small pieces
(b1 mm3) and fixed in half-strength Karnovsky
fixative for 4 h at room temperature. After washing
in 0.1 M phosphate buffer (pH 7.4), the samples
31CD151 as a cause of epidermolysis bullosawere immersed in 1.3% aqueous osmium tetroxide
(TAAB Laboratories, Berkshire, UK) for 2 h, followed
by incubation in 2% uranyl acetate (Bio-Rad,
Hertfordshire, UK), and dehydrated in a graded
ethanol series, and then embedded in epoxy resin via
propylene oxide (TAAB Laboratories). Ultra-thin sec-
tions were stained with uranyl acetate and lead citrate
andexamined in aPhilipsCM10 transmission electron
microscope (Philips, Eindhoven, The Netherlands).Acknowledgments
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